Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Replimune Group (REPL) Forecast
NewsEarningsReplimune Group (REPL) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestEdge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Replimune Group Stock Price, Quotes and Forecasts | NASDAQ:REPL | Benzinga
Explore Replimune Group stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REPL.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Replimune Group (REPL) stock?
You can purchase shares of Replimune Group (NASDAQ:REPL) through any online brokerage.
Who are Replimune Group (REPL) competitors?
Other companies in Replimune Group’s space includes: Immunome (NASDAQ:IMNM), ARS Pharmaceuticals (NASDAQ:SPRY), Gyre Therapeutics (NASDAQ:GYRE), Cogent Biosciences (NASDAQ:COGT) and Prothena Corp (NASDAQ:PRTA).
What is the forecast, or price target, for Replimune Group (REPL) stock?
Replimune Group has a consensus price target of $32.54.
What is the current price for Replimune Group (REPL)?
The stock price for Replimune Group (NASDAQ: REPL) is $11.885 last updated March 4, 2025 at 9:45 AM EST.
Does Replimune Group (REPL) pay a dividend?
There are no upcoming dividends for Replimune Group.
When is Replimune Group (NASDAQ:REPL) reporting earnings?
Replimune Group’s Q4 earnings are confirmed for Thursday, May 15, 2025.
Is Replimune Group (REPL) going to split?
There is no upcoming split for Replimune Group.
What sector and industry does Replimune Group (REPL) operate in?
Replimune Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.